# Novo Nordisk

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/novo-nordisk/

## Facts

| Field | Value |
| --- | --- |
| Country | DK |
| Description | Danish pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320322436 |
| ROR ID | https://ror.org/0435rc536 |
| Works | 46,090 |

## Funder papers

Showing 15 of 46.

- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes](https://scholariq.org/papers/glucose-control-and-vascular-complications-in-veterans-with-type-2-diabetes/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://scholariq.org/papers/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2/)
- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial](https://scholariq.org/papers/patiromer-for-the-management-of-hyperkalemia-in-heart-failure-with-reduced/)
- [Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial](https://scholariq.org/papers/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovascular-disease/)
- [Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study](https://scholariq.org/papers/liraglutide-3-mg-on-weight-body-composition-and-hormonal-and-metabolic/)
- [Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials](https://scholariq.org/papers/effects-of-once-weekly-subcutaneous-semaglutide-on-kidney-function-and-safety-in/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [Severity of COVID-19 at elevated exposure to perfluorinated alkylates](https://scholariq.org/papers/severity-of-covid-19-at-elevated-exposure-to-perfluorinated-alkylates/)
- [Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial](https://scholariq.org/papers/effects-of-semaglutide-on-heart-failure-outcomes-in-diabetes-and-chronic-kidney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.